TUBB4A
ENSG00000104833
Target class
Structural protein
Chromosome
19
Approved drugs
19
Clinical candidates (approved and in development)
84
- Approved drugs
- 19
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 84
- Chemical probe available
- No
- Other names
- beta-5
- Target name
- TUBB4A
- Gene name
- Tubulin beta 4A class IVa
- Gene symbol
- TUBB4A
- Protein name
- Tubulin beta-4A chain (Tubulin 5 beta) (Tubulin beta-4 chain)
- TUBB4
- DYT4
- Gene biotype
- Protein coding
- Gene family
- Tubulin beta family
- Target class
- Structural protein
- Target type
- Human gene
- Tissues expressed in
- 27
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 988.75
- Tissue specificity (Gini)
- 0.824
- Tissue specificity (tau)
- 0.933
- KEGG gene identifiers
- hsa:10382
- Protein interaction confidence
- 0.8487
- Protein interaction partners
- 30
- R-HSA-1445148
- R-HSA-190840
- R-HSA-190861
- R-HSA-2132295
- R-HSA-2467813
- R-HSA-2500257
- R-HSA-2565942
- R-HSA-3371497
- R-HSA-380259
- R-HSA-380270
- R-HSA-380284
- R-HSA-380320
- R-HSA-389957
- R-HSA-389960
- R-HSA-389977
- R-HSA-437239
- R-HSA-5610787
- R-HSA-5620912
- R-HSA-5620920
- R-HSA-5620924
- R-HSA-5626467
- R-HSA-5663220
- R-HSA-6807878
- R-HSA-6811434
- R-HSA-6811436
And 12 more, listed on the interactive page.
- End position
- 6502848
- Start position
- 6494319
- Chromosome
- 19
- Strand
- Reverse
- Cytoplasm, cytoskeleton.
- Basal body
- Cytokinetic bridge
- End piece
- Flagellar centriole
- Microtubules
- Mitotic spindle
- Primary cilium
- Primary cilium tip
- Principal piece
- Tissue specificity (tau)
- 0.932633
- Expression inequality (Gini)
- 0.824425
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 988.75
- Brain - Cerebellum
- 895.32
- Brain - Spinal cord (cervical c-1)
- 446.23
- Brain - Frontal Cortex (BA9)
- 305.65
- Brain - Cortex
- 258.5
Expression in transcripts per million
- Brain - Cerebellar Hemisphere988.75
- Brain - Cerebellum895.32
- Brain - Spinal cord (cervical c-1)446.23
- Brain - Frontal Cortex (BA9)305.65
- Brain - Cortex258.5
- Brain - Substantia nigra186.65
- Brain - Hippocampus185.54
- Brain - Hypothalamus176.08
- Brain - Nucleus accumbens (basal ganglia)174.77
- Brain - Caudate (basal ganglia)170.04
- Brain - Anterior cingulate cortex (BA24)168.73
- Brain - Putamen (basal ganglia)168.28
- Brain - Amygdala131.6
- Adrenal Gland109.64
- Testis80.06
- Nerve - Tibial30.81
- Spleen6.77
- Colon - Sigmoid4.81
- Cells - EBV-transformed lymphocytes2.55
- Esophagus - Muscularis2.18
- Esophagus - Gastroesophageal Junction2.11
- Colon - Transverse1.99
- Small Intestine - Terminal Ileum1.58
- Skin - Sun Exposed (Lower leg)1.5
- Pituitary1.3
And 29 more, listed on the interactive page.
Biological processes
- GO:0031115
- GO:0005634
- GO:0005829
- GO:0005874
- GO:0005929
- GO:0005930
- GO:0015630
- GO:0045171
- GO:0070062
- GO:0072686
- GO:0097228
- GO:0097229
- GO:0097542
- GO:0005509
- GO:0005515
Related records
Trials (9,123)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Drugs (89)
- ABT-751 Tubulin beta inhibitor
- AGS-16C3F Tubulin disrupting agent
- Anetumab ravtansine Tubulin inhibitor
- ANG1005 Tubulin inhibitor
- Anvatabart opadotin Tubulin inhibitor
- Aprutumab ixadotin Tubulin inhibitor
- ASG-5ME Tubulin inhibitor
- AVE-9633 Tubulin inhibitor
- Azintuxizumab vedotin Tubulin inhibitor
- Belantamab mafodotin Tubulin inhibitor
- BIIB-015 Tubulin inhibitor
- Bivatuzumab mertansine Tubulin inhibitor
- BMS-275183 Tubulin stabiliser
- Brentuximab vedotin Tubulin inhibitor
- Cabazitaxel Tubulin inhibitor
- Cantuzumab mertansine Tubulin inhibitor
- Cantuzumab ravtansine Tubulin inhibitor
- Colchicine Tubulin inhibitor
- Coltuximab ravtansine Tubulin inhibitor
- Crolibulin Tubulin inhibitor